Vivek Rakholiya

Thanks a lot for the opportunity and apologies in advance if my questions are very basic. I'm very new to the company. I wanted to understand firstly on the peptide front, a listed peer claims to have also developed the capability of making the full peptide chain , right from fragments to the APIs, and they have even started expanding their capacity for the same.

Great. Thanks a lot for that answer. Just stepping back in terms of molecules and complexities, would it be the correct understanding that the TAM of peptide is larger than that of oligonucleotides? Also, just wanted to confirm , if between say peptide, oligonucleotides, and ADCs, how would you rank yourself on the basis of the complexity of the subject that you work with, your capability and the TAM of these areas…

Congratulations on a great set of numbers. I wanted to have an understanding of any of the reasons for the leadership transition with Saharsh taking over as CEO and MD from Sucheth, who become a Vice Chairman.

Thank you. Thanks a lot for the answers, sir. The next question is that as per the S&P Global data from March, the global PE/VC biotech funding has declined sharply since 2021. I understand that you answered partially, but how is this trend impacting your business, the RFQs and client inquiries? And how do you plan to navigate this trend?